{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:01:40Z","timestamp":1784134900582,"version":"3.55.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81370327"],"award-info":[{"award-number":["81370327"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900452"],"award-info":[{"award-number":["81900452"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Recent studies suggest apelin has multiple protective effects in some cardiovascular diseases. However, there are few data concerning apelin levels in patients with obstructive hypertrophic cardiomyopathy (OHCM) or the relationship between apelin levels and severity of OHCM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We studied 88 patients with OHCM and 32 control subjects with matched age and sex distribution. Complete medical history was collected and related examinations were performed. Cardiac magnetic resonance (CMR) and echocardiography were employed to characterize cardiac morphology and function. Plasma apelin was measured by enzyme-linked immunosorbent assay (ELISA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Plasma apelin levels were significantly lower in patients with OHCM than those in control subjects (96.6 \u00b1 34.3 vs. 169.4 \u00b1 62.5 \u03bcg\/L, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). When patients with OHCM were divided into two groups according to the mean value of plasma apelin, patients with lower apelin levels (plasma apelin \u2264 96.6 \u03bcg\/L) had greater septal wall thickness (SWT; 25.6 \u00b1 5.5 vs. 23.2 \u00b1 4.3 mm, <jats:italic>p<\/jats:italic> = 0.035) and less right ventricular end-diastolic diameter (RVEDD; 20.4 \u00b1 3.3 vs. 23.0 \u00b1 3.6 mm, <jats:italic>p<\/jats:italic> = 0.001). Consistently, plasma apelin levels were inversely correlated with SWT (<jats:italic>r<\/jats:italic> = \u22120.334, <jats:italic>p<\/jats:italic> = 0.002) and positively correlated with RVEDD (<jats:italic>r<\/jats:italic> = 0.368, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). Besides, plasma apelin levels were inversely correlated with Ln (NT-proBNP) (<jats:italic>r<\/jats:italic> = \u22120.307, <jats:italic>p<\/jats:italic> = 0.008) and positively correlated with body mass index (BMI; <jats:italic>r<\/jats:italic> = 0.287, <jats:italic>p<\/jats:italic> = 0.008). On multivariate analysis, the SWT was independently associated with decreasing plasma apelin, while the RVEDD was independently associated with increasing plasma apelin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Plasma apelin levels are reduced in patients with OHCM. The apelin levels are inversely related to SWT and positively related to RVEDD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.904892","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T04:41:33Z","timestamp":1655440893000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Significance and Determinants of Plasma Apelin in Patients With Obstructive Hypertrophic Cardiomyopathy"],"prefix":"10.3389","volume":"9","author":[{"given":"Chengzhi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruofei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiansong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zening","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23042195","article-title":"Critical evaluation of current hypotheses for the pathogenesis of hypertrophic cardiomyopathy.","volume":"23","author":"Usaj","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","article-title":"Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC State-of-the-Art review.","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1006\/bbrc.1998.9489","article-title":"Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor.","volume":"251","author":"Tatemoto","year":"1998","journal-title":"Biochem Biophys Res Commun."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2020.02.07","article-title":"Apelin\/Elabela-APJ: a novel therapeutic target in the cardiovascular system.","volume":"8","author":"Liu","year":"2020","journal-title":"Ann Transl Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10741-015-9475-x","article-title":"Effects of apelin on the cardiovascular system.","volume":"20","author":"Folino","year":"2015","journal-title":"Heart Fail Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nature11263","article-title":"APJ acts as a dual receptor in cardiac hypertrophy.","volume":"488","author":"Scimia","year":"2012","journal-title":"Nature."},{"key":"B7","first-page":"733","article-title":"Effect of Apelin on angiotensin II-induced cardiomyocyte hypertrophy with its mechanism in experimental rats.","volume":"29","author":"Zhou","year":"2014","journal-title":"Chin Circ J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC).","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.echo.2011.03.006","article-title":"American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography.","volume":"24","author":"Nagueh","year":"2011","journal-title":"J Am Soc Echocardiogr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2217\/bmm-2019-0225","article-title":"Prevalence and determinants of elevated D-dimer in patients with hypertrophic cardiomyopathy.","volume":"14","author":"Yang","year":"2020","journal-title":"Biomark Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.15386\/cjmed-380","article-title":"The Apelin-APJ system in the evolution of heart failure.","volume":"88","author":"Goidescu","year":"2015","journal-title":"Clujul Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.amjcard.2015.09.006","article-title":"Significance and determinants of cardiac troponin i in patients with obstructive hypertrophic cardiomyopathy.","volume":"116","author":"Zhang","year":"2015","journal-title":"Am J Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of hypertrophic cardiomyopathy: JACC State-of-the-Art review.","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2013.09.001","article-title":"Apelin and its receptor APJ in cardiovascular diseases.","volume":"428","author":"Yu","year":"2014","journal-title":"Clin Chim Acta."},{"key":"B16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1536\/ihj.13-234","article-title":"Apelin: a potential marker of coronary artery stenosis and atherosclerotic plaque stability in ACS patients.","volume":"55","author":"Zhou","year":"2014","journal-title":"Int Heart J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/01.res.0000033522.37861.69","article-title":"Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility.","volume":"91","author":"Szokodi","year":"2002","journal-title":"Circ Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ejheart.2005.10.007","article-title":"Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure.","volume":"8","author":"Chong","year":"2006","journal-title":"Eur J Heart Fail."},{"key":"B19","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.cardfail.2010.02.004","article-title":"Myocardial apelin production is reduced in humans with left ventricular systolic dysfunction.","volume":"16","author":"Chandrasekaran","year":"2010","journal-title":"J Card Fail."},{"key":"B20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.cardfail.2013.05.004","article-title":"Effects of acute intravenous infusion of apelin on left ventricular function in dogs with advanced heart failure.","volume":"19","author":"Wang","year":"2013","journal-title":"J Card Fail."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1161\/CIRCULATIONAHA.109.911339","article-title":"Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure.","volume":"121","author":"Japp","year":"2010","journal-title":"Circulation."},{"key":"B22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.yjmcc.2013.07.002","article-title":"Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction.","volume":"63","author":"Ceylan-Isik","year":"2013","journal-title":"J Mol Cell Cardiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1097\/HJH.0b013e328344da76","article-title":"Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction.","volume":"29","author":"Przewlocka-Kosmala","year":"2011","journal-title":"J Hypertens."},{"key":"B24","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/s0006-291x(03)01424-4","article-title":"Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure.","volume":"308","author":"Foldes","year":"2003","journal-title":"Biochem Biophys Res Commun."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129433","article-title":"17Beta-Estradiol and estrogen receptor alpha protect right ventricular function in pulmonary hypertension via BMPR2 and apelin.","volume":"131","author":"Frump","year":"2021","journal-title":"J Clin Invest."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.904892\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T04:41:36Z","timestamp":1655440896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.904892\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":25,"alternative-id":["10.3389\/fcvm.2022.904892"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.904892","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"article-number":"904892"}}